Compare Endeavour Silver Corp (EXK) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Endeavour Silver Corp vs Novavax Inc — how do they compare? Endeavour Silver Corp trades at $8.65 (market cap $2.54B), while Novavax Inc trades at $12.75 (market cap $1.82B). The key difference: Endeavour Silver Corp is the larger of the two by market cap, and Novavax Inc is trading nearer its 52-week high, Endeavour Silver Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Endeavour Silver Corp for 25 Days and Novavax Inc for 59 Days on average.
| EXK | NVAX | |
|---|---|---|
Market Cap | $2.54B | $1.82B |
Volume | 7,077,330 | 6,198,505 |
Sector | Basic Materials | Health |
52-Week High | $14.12 | $12.75 |
52-Week Low | $7.07 | $6.22 |
Typical Hold Time | 25 Days | 59 Days |
Enterprise Value | $2.54B | $1.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Endeavour Silver (EXK) trades at $8.57, up 3.0% today, amid a bearish technical signal from moving averages but with neutral oscillators. The company reported a net loss of $119.1 million in 2025, though 2026 projections show a turnaround to a $66 million net profit. Recent news highlights operational progress at the Terronera and Kolpa mines, alongside temporary disruptions now resolved.
The outlook is mixed: strong analyst buy consensus (78.57%) and projected 2026 profitability support upside, but high P/E of 42.85 and operational risks from mine blockades pose challenges. Investment appeal hinges on execution of growth projects and silver price stability.
Novavax (NVAX) trades at $11.01, down 1.87% on the day, with a bullish technical signal from moving averages and a strong buy consensus from analysts (73.9% buy ratings). The company reported a net income of $440.3M in 2025, a significant turnaround from prior losses, though 2026 projections show a return to negative margins. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivots toward its Matrix-M adjuvant platform through partnerships.
The outlook is mixed: near-term catalysts include partnership-driven growth and vaccine approvals, but persistent cash burn and projected 2026 losses pose risks. Investor sentiment is buoyed by recent earnings beats and strategic shifts, yet execution on profitability remains critical for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Endeavour Silver Corp
Endeavour Silver is a mid-tier precious metals mining company. It operates silver-gold mines in Mexico and is focused on growing its production and reserves through exploration and the development of new mining projects.
Read more on EXK →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
